PMID- 23011089
OWN - NLM
STAT- MEDLINE
DCOM- 20131030
LR  - 20220801
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr
TI  - The effect of anti-tuberculosis treatment on levels of anti-phospholipid and 
      anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis.
PG  - 949-53
LID - 10.1007/s00296-012-2487-0 [doi]
AB  - The aim of this study is to determine the prevalence and effect of 
      anti-tuberculosis treatment on anti-phospholipid antibodies and anti-neutrophil 
      cytoplasmatic antibodies (ANCA) in patients with active mycobacterial infections. 
      Thirty-three consecutive patients (age 56 years, 26 males) with recently 
      diagnosed active tuberculosis (TB) were enrolled. Data included clinical disease 
      features, symptom duration, multidrug resistance and presence of HIV. Serum 
      samples taken before and after TB treatment were frozen at -20  degrees C and tested for 
      anti-cardiolipin IgG (aCL), anti-beta2 glycoprotein IgG (anti-beta2GPI), 
      anti-prothrombin, anti-proteinase 3 (PR3), myeloperoxidase (MPO), 
      bactericidal/permeability (BPI) and lactoferrin. Thirty percent of patients had 
      higher than cut-off value for anti-beta2GPI, and 9 % had increased aCL. The levels 
      of antibodies against beta2GPI and aCL normalized post-treatment. A substantial 
      proportion of patients had high baseline anti-PR3, MPO, BPI and lactoferrin 
      levels. Most anti-lactoferrin and anti-MPO levels decreased post-treatment, while 
      anti-PR3 increased in most of the baseline-positive patients. Some patients had 
      de novo anti-PR3 and MPO formation after 6-month treatment. Patients with active 
      TB have significantly increased anti-beta2GPI and ANCA titers. While anti-beta2GPI 
      titers normalize post-treatment, ANCA behave in a complex way. Anti-TB treatment 
      may induce normalization of anti-lactoferrin and anti-MPO, and de novo anti-PR3 
      and MPO formation.
FAU - Elkayam, Ori
AU  - Elkayam O
AD  - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, 
      University of Tel Aviv, 6 Weizman Street, 64239 Tel Aviv, Israel. 
      oribe14@netvision.net.il
FAU - Bendayan, Daniele
AU  - Bendayan D
FAU - Segal, Refael
AU  - Segal R
FAU - Shapira, Yinon
AU  - Shapira Y
FAU - Gilburd, Boris
AU  - Gilburd B
FAU - Reuter, Sandra
AU  - Reuter S
FAU - Agmon-Levin, Nancy
AU  - Agmon-Levin N
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - eng
PT  - Journal Article
DEP - 20120804
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Antineutrophil Cytoplasmic/*blood/immunology
MH  - Antibodies, Antiphospholipid/*blood/immunology
MH  - Antitubercular Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Tuberculosis/blood/*drug therapy/immunology
EDAT- 2012/09/27 06:00
MHDA- 2013/10/31 06:00
CRDT- 2012/09/27 06:00
PHST- 2012/02/11 00:00 [received]
PHST- 2012/07/07 00:00 [accepted]
PHST- 2012/09/27 06:00 [entrez]
PHST- 2012/09/27 06:00 [pubmed]
PHST- 2013/10/31 06:00 [medline]
AID - 10.1007/s00296-012-2487-0 [doi]
PST - ppublish
SO  - Rheumatol Int. 2013 Apr;33(4):949-53. doi: 10.1007/s00296-012-2487-0. Epub 2012 
      Aug 4.